Opthea Ltd. is a clinical stage biopharmaceutical company, which engages in the development of biological therapeutics for the treatment of progressive retinal diseases. The company is headquartered in Melbourne, Victoria. The firm is engaged in developing novel therapies to address the unmet need in the treatment of prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate, sozinibercept (OPT-302), is being evaluated in two pivotal Phase 3 clinical trials for use in combination with standard-of-care anti-VEGF-A monotherapies for the treatment of wet AMD and DME. The firm has also manufactured OPT-302 for use in Phase III clinical trials, conducts activities to support the commercialization of the product and expanded its management team in the United States to facilitate broader oversight and execution of its Phase III program. Its development activities are based on an intellectual property portfolio covering key targets (Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3).
Follow-Up Questions
CKDXF hissesinin fiyat performansı nasıl?
CKDXF 'in mevcut fiyatı $0 'dir, son işlem günde 0% decreased etti.
Opthea Ltd için ana iş temaları veya sektörler nelerdir?
Opthea Ltd Biotechnology endüstrisine ait ve sektör Health Care 'dir
Opthea Ltd 'in piyasa değerlemesi nedir?
Opthea Ltd 'in mevcut piyasa değerlemesi $0 'dir
Opthea Ltd al, sat, yoksa beklemeli mi?
Wall Street analistlerine göre, 5 analist Opthea Ltd için analist derecelendirmeleri gerçekleştirdi, bunlar 0 güçlü al, 1 al, 3 tut, 4 sat ve 0 güçlü sat içermektedir
